KA
IDXX icon

Klingman & Associates’s Idexx Laboratories IDXX Stock Holding History

Klingman & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-310
Closed -$210K – 340
2025
Q4 		$210K Buy
+310
New +$211K 0.01% 315
2025
Q1 		– Sell
-597
Closed -$247K – 265
2024
Q4 		$247K Sell
597
-8
-1% -$3.51K 0.02% 228
2024
Q3 		$306K Buy
+605
New +$294K 0.02% 211
2016
Q2 		– Sell
-280
Closed -$22K – 383
2016
Q1 		$22K Hold
280
– – 0.01% 246
2015
Q4 		$20K Hold
280
– – 0.01% 266
2015
Q3 		$20K Hold
280
– – 0.01% 261
2015
Q2 		$18K Hold
280
– – 0.01% 266
2015
Q1 		$22K Hold
280
– – 0.01% 228
2014
Q4 		$20K Buy
+280
New +$19.6K 0.01% 236

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Klingman & Associates's IDXX Position: Q1 2026 in Review

Klingman & Associates sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 310 shares — an estimated $210K sold.

Klingman & Associates first reported a position in IDXX in Q4 2014 and held it in 9 quarters. The position peaked at $306K in Q3 2024. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Klingman & Associates reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
  • Klingman & Associates sold 310 Idexx Laboratories shares in Q1 2026, an estimated $210K.
  • Klingman & Associates first reported a position in Idexx Laboratories in Q4 2014 and held it in 9 quarters.
  • Klingman & Associates's Idexx Laboratories position peaked at $306K in Q3 2024.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Klingman & Associates's 13F filing for Q1 2026, filed 14 May 2026.